Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual London Healthcare Conference on November 18, starting at 3:00 a.m. ET. The presentation will be accessible via the provided link and will be archived on Keros’ website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders, with key products including KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.
- None.
- None.
LEXINGTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the Jefferies Virtual London Healthcare Conference.
The presentation will be available on Thursday, November 18 starting at 3:00 a.m. ET at https://wsw.com/webcast/jeff201/kros/1864242 and archived in the Investors section of the Keros website at https://ir.kerostx.com. A replay will be available for 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
Investor Contact:
Mike Biega
mbiega@soleburytrout.com
617-221-9660
FAQ
When will Keros present at the Jefferies Virtual London Healthcare Conference?
Who is presenting for Keros at the conference?
Where can I watch Keros' presentation?
What is the focus of Keros Therapeutics?
What are the main product candidates of Keros?
